对神经退行性疾病的药物重新定位
Halak Shukla1, Diana John1, Shuvomoy Banerjee1
1Department of Biotechnology and Bioengineering, Institute of Advanced Research (IAR), Gandhinagar, Gujarat, India.
Progress in molecular biology and translational science
|June 28, 2024
概括
神经退行性疾病 (NDDs) 影响全球数百万人. 这项研究探讨了药物重用作为一种具有成本效益的策略,以找到更好的治疗阿尔茨海默氏症等疾病的方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 神经退行性疾病 (NDD) 是一种进展性神经元疾病,影响大脑和脊髓,导致感觉和运动功能障碍.
- 常见的NDD包括阿尔茨海默氏病 (AD),帕金森病 (PD),亨廷顿病 (HD),多发性硬化症 (MS) 和肌缩侧面硬化症 (ALS).
- 随着年龄的增长,NDD的患病率增加,对老年人群构成重大挑战,全球影响超过10亿人.
研究的目的:
- 探索药物重定向的潜力,作为一种有效,安全和具有成本效益的方法来治疗NDD.
- 确定和讨论用于治疗主要神经退行性疾病的重用药物.
- 强调需要进一步研究NDD的潜在机制和分子细节,以改善治疗点.
主要方法:
- 审查和讨论关于神经退行性疾病药物重用现有文献.
- 分析当前药物的疗效在治疗NDDs.
- 识别潜在的治疗点,以改变疾病病理.
主要成果:
- 药物再利用为开发有效的NDD治疗方法提供了一个有希望的途径.
- 一些药物正在评估它们在治疗AD,PD,HD,MS和ALS方面的有效性.
- 早期检测策略和药物重定向是改善NDD管理的关键步骤.
结论:
- 药物再利用提供了一个可行的和有效的策略,以加快神经退行性疾病的治疗方法的开发.
- 进一步的研究对于充分理解NDD机制和优化治疗干预至关重要.
- 这种方法可以改善患者的治疗结果,并降低与NDD相关的医疗保健成本.
相关概念视频
01:22Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
01:15Parkinson's Disease: Overview
523
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
523
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:24Parkinson's Disease: Treatment
254
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
254
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
118
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
118